fda bans compounded semaglutide and tirzepatide GLP-1 ban: What providers need to know FDA says 'no clinical need'

Does this include hands-on injecting practice

What is PT-141 and where does it come from

Flavors In Bundle: Blueberry Muffin, Chocolate Delight, Chocolate Peanut Butter Cup & Lemon Squares

Semaglutide activates (an agonist) the GLP-1 receptor, while tirzepatide is in a new class of dual agonists: it activates (mimics) both the GLP-1 receptor and GIP receptors (Gastric inhibit polypeptide is also known as glucose-dependent insulinotropic polypeptide.) The potency of activation for tirzepatide is 5-fold more for GIPR than GLP1

For now, staying informed about these developments while working with healthcare providers on evidence-based approaches remains the best strategy for anyone interested in advanced weight management options